Breaking News on Global Pharmaceutical Technology & Manufacturing

Headlines > All Ingredients News

ScinoPharm showcases water treatment tech at Baxdela API plant

17-Aug-2017 - ScinoPharm has emphasised its compliance with waste water treatment rules, weeks after being contracted to supply API for Melinta Therapeutics’ antibiotic Baxdela.

GSK opens API facility in Scotland

16-Aug-2017 - GlaxoSmithKline has officially opened its aluminium salts facility in Montrose, Scotland.

SK Capital will pay $110m for Perrigo's drug ingredients business

14-Aug-2017 - SK Capital has said it will buy Perrigo Company Plc’s drug ingredients business for $110m (€85m) in cash.

Avara agrees to buy ex-Hospira plant in Italy from Pfizer

10-Aug-2017 - Avara Pharmaceutical Services has agreed to buy Pfizer Inc. sterile drug manufacturing facility in Liscate, Italy.


Teva confirms API plant will be among 15 sites shut in cost cutting plan

07-Aug-2017 - Teva Pharmaceutical Industries Ltd has confirmed its API plant in Netanya, Israel will close as part of the cost reduction programme announced last week. 

Cambrex sees Q2 revs and earnings rise, confirms interest in takeovers

07-Aug-2017 - Cambrex Corporation says higher demand for APIs for controlled substances and branded drugs drove Q2 growth and confirms it is on the lookout for acquisitions. 

News in brief

Pfizer's API business revenue falls 13% on lower international sales

03-Aug-2017 - Revenue generated by Pfizer’s API and contracting business fell in the second quarter.

Scinopharm hired to make API for skin infection antibiotic Baxdela

03-Aug-2017 - Melinta Therapeutics has hired ScinoPharm to make the active pharmaceutical ingredient (API) for Baxdela, an antibiotic for skin infections that was recently approved by the US FDA.

Fosun and KKR extend deadline for $1.2bn Gland Pharma deal

01-Aug-2017 - Shanghai Fosun Pharma and KKR have agreed to extended the termination date for the former's proposed $1.2bn (€1bn) takeover of Gland Pharma.

Merck & Co API operations hit by cyberattack yet to restart production

31-Jul-2017 - API operations hit by the Petya cyberattack have not been restored according to Merck & Co Inc, which expects difficulties fulfilling some product orders and lower 2017 profits partly due to the hack. 

Takeda licenses Zejula in deal that will see Tesaro supply it with API

31-Jul-2017 - Takeda has agreed to pay $100m (€85m) upfront for rights to make and sell to Tesaro Inc’s drug Zejula in Japan, South Korea, Taiwan, Russia and Australia.

Avantor site launches with biopharma lean

27-Jul-2017 - Avantor has opened a research centre in New Jersey, US offering gene to protein expression and drug delivery contract services.

Dirty work for drug makers: wastewater can be used for antibiotics development, says researcher

27-Jul-2017 - A researcher at South Africa’s Stellenbosch University (SU) says biosurfactants made by bugs in municipal wastewater could help drug makers develop new antibiotics.

Reig Jofre says it has resolved penicillin raw materials supply issue

27-Jul-2017 - Raw material supply problems that impacted its penicillin business last year have been resolved according to Reig Jofre.

Lonza sets CHF7.5bn 2022 sales target citing pharma drivers

26-Jul-2017 - Lonza Group AG has predicted it will generate annual revenue of CHF7.5bn ($7.9bn) by 2022, citing recent acquisition Capsugel and its new Visp-based Ibex manufacturing service as drivers.

News in brief

Unichem outlines manufacturing plan for generic Hyzaar

26-Jul-2017 - Unichem Laboratories Limited has confirmed it will make its generic version of Hyzaar for the US market at three plants in India.

STA to supply intermediate for Tesaro 's $117k-a-year cancer drug Zejula

25-Jul-2017 - Tesaro Inc has hired STA Pharmaceutical Co. Ltd to supply intermediates for its recently approved, $117k-a-year, ovarian cancer drug Zejula (niraparib).

Chongquing Succeway made APIs in undeclared plant and faked records says ANSM

24-Jul-2017 - French regulators says Chongquing Succeway Pharmaceutical Co Ltd should recall APIs made at its plant in Chongquing after inspectors found evidence of record manipulation and an undeclared manufacturing area.

TPI Enterprises buys Vistin opiates assets and confirms Portugal plant plan

21-Jul-2017 - TPI Enterprises has bought Vistin Pharma ASA’s opiates and tabletting division for A$25.4m ($201.m) in a deal designed to expand the firm beyond its narcotic raw materials business.

WHO prequalifies Mylan's India unit to supply TB drug API

20-Jul-2017 - The WHO has prequalified Indian-based Mylan Laboratories Ltd to supply the tuberculosis drug ingredient protionamide.

Rousselot is first gelatin firm to join IPEC Europe

17-Jul-2017 - Gelatin firm Rousselot BV has joined IPEC Europe describing the move as an opportunity to contribute to the development of regulatory standards for pharmaceutical excipients.

Nitto Denko Avecia’s expanded API site to open in Massachusetts, US

17-Jul-2017 - Nitto Denko Avecia has announced it will launch its expanded Milton, Massachusetts-based oligonucleotide API facility next month.

update - includes statement from Gilead

Gilead HIV drug API sourcing suit reopened by US Appeal Court

11-Jul-2017 - Gilead Sciences Inc. faces renewed allegations it bought an API used in three of its HIV drugs from an unapproved Chinese supplier after a US Court of Appeals ruling.

News in brief

Canada's Medicure exercises option to buy US-Indian API firm Apicore

11-Jul-2017 - Medicure Inc. has exercised an option to buy New Jersey, US –based active pharmaceutical ingredient (API) maker Apicore Inc.

Newlink expands indoximod IP with US prodrug patent

10-Jul-2017 - Newlink Genetics Corporation has expended its indoximod IP portfolio weeks after data suggested the cancer drug may make Provenge and Keytruda more effective.

Key Industry Events


Access all events listing

Our events, Shows & Conferences...